We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Gains on Product Launches, Competition Rife
Read MoreHide Full Article
On Aug 21, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL - Free Report) . The company develops and markets end-to-end automation solutions for the medication use process.
Omnicell’s second-quarter 2017 performance was impressive with a year-over-year increase in earnings and revenues. The company gained on revenues banking on its recent launches and strategic partnerships. Notably, Omnicell recently launched AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launched XT Series Automated Supply Dispensing system in July 2017.
During the quarter, the company also launched the controlled substance dispenser, a module-providing secured workflow for dispensing and administration of controlled substance. However, weak margins raise concern.
On the flip side, Omnicell faces intense competition in the medication management and supply chain solutions market. Also, the company has adopted several strategies to drive its top line including portfolio expansion, acquisitions and further penetration into the medication adherence market. Thus, the company continues to battle escalating costs.
Overall, in majority of the last three months, Omnicell has been trading above its industry. As per the latest share price movement, the stock has gained 20.8%, significantly lower than the broader industry’s addition of 2.5%.
Zacks Rank & Key Picks
Omnicell currently carries a Zacks Rank 3 (Hold). A few top-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Stryker Corporation (SYK - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Stryker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 19.4% over the last six months.
Stryker has a long-term expected earnings growth rate of 10.00%. The stock has rallied roughly 12.8% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 28.6% over the last six months.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Image: Bigstock
Omnicell (OMCL) Gains on Product Launches, Competition Rife
On Aug 21, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL - Free Report) . The company develops and markets end-to-end automation solutions for the medication use process.
Omnicell’s second-quarter 2017 performance was impressive with a year-over-year increase in earnings and revenues. The company gained on revenues banking on its recent launches and strategic partnerships. Notably, Omnicell recently launched AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launched XT Series Automated Supply Dispensing system in July 2017.
During the quarter, the company also launched the controlled substance dispenser, a module-providing secured workflow for dispensing and administration of controlled substance. However, weak margins raise concern.
On the flip side, Omnicell faces intense competition in the medication management and supply chain solutions market. Also, the company has adopted several strategies to drive its top line including portfolio expansion, acquisitions and further penetration into the medication adherence market. Thus, the company continues to battle escalating costs.
Overall, in majority of the last three months, Omnicell has been trading above its industry. As per the latest share price movement, the stock has gained 20.8%, significantly lower than the broader industry’s addition of 2.5%.
Zacks Rank & Key Picks
Omnicell currently carries a Zacks Rank 3 (Hold). A few top-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Stryker Corporation (SYK - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Stryker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 19.4% over the last six months.
Stryker has a long-term expected earnings growth rate of 10.00%. The stock has rallied roughly 12.8% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 28.6% over the last six months.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>